NCT05940363View on ClinicalTrials.gov

The National Program for the Improvement of Management of Fetal Congenital Heart Disease in China

Not yet recruitingOBSERVATIONAL
Enrollment

9,000

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

September 1, 2023

Study Completion Date

June 1, 2026

Conditions
Congenital Heart Disease in PregnancyPrenatal DiagnosisFetal Echocardiography
Interventions
COMBINATION_PRODUCT

Improvement on Prenatal Screening and Treatment Capabilities for Congenital Heart Disease with a Comprehensive Diagnosis and Treatment Program Incorporating New Technologies

To investigate and evaluate the capacity of prenatal screening, diagnosis and counseling for fetal heart disease based on medical institutions; Improving capacity for prenatal screening, diagnosis and counselling through integrated products embedded with new technologies.

All Listed Sponsors
lead

Beijing Anzhen Hospital

OTHER

NCT05940363 - The National Program for the Improvement of Management of Fetal Congenital Heart Disease in China | Biotech Hunter | Biotech Hunter